

Media Release

Excellent results for Straumann in independent peri-implantitis study

- *Large retrospective study¹ of dental implants in broad clinical setting: 427 patients, 1578 implants from various manufacturers, 9-year follow-up*
- *Significantly lower odds ratios for moderate/severe peri-implantitis with Straumann Tissue Level SLA implants than with the other implant systems evaluated*
- *Study published in peer-reviewed Journal of Dental Research*
- *Findings highly relevant for dentists who base their choice of implant on independent clinical evidence*

Basel, 20 January 2016 – Results from a large independent study on peri-implantitis have shown there are substantial differences between implant systems and the occurrence of peri-implantitis, an inflammation around dental implants that leads to implant loss if not treated.

Using the national data register of the Swedish Social Insurance Agency, Dr Jan Derks and colleagues from Gothenburg University in Sweden randomly selected 427 implant patients from a population of approximately 25 000 patients treated 9 years previously by more than 800 clinicians. The selected patients were assessed for typical indicators of peri-implantitis, including bone loss, bleeding, and pocket depth around their implants.

The investigators observed that the extent of moderate/severe peri-implantitis² differed between the implant systems and that the odds ratio of developing it was more than three times higher in the patients treated with Nobel Biocare and Astra Tech Implant System implants. With some exceptions, the Nobel Biocare implants had a TiUnite[®] surface and the Astra Tech implants had a TiOblast[®] surface; all the Straumann implants were Tissue Level SLA[®].

The results, which were presented at the 2015 EAO and have now been published in the Journal of Dental Research¹, add weight to previously reported findings showing high success rates with Straumann implants^{3,4,5,6,7}. The findings are highly relevant for dentists who base their choice of implant on independent clinical evidence.

Read the study: <http://jdr.sagepub.com/content/95/1/43.abstract>

Watch the video: https://youtu.be/0m3i5_4DDOw

About Straumann

Headquartered in Basel, Switzerland, Straumann (SIX: STMN) is a global leader in implant, restorative and regenerative dentistry. In collaboration with leading clinics, research institutes and universities, Straumann researches, develops and manufactures dental implants, instruments, prosthetics and biomaterials for use in tooth replacement and restoration solutions or to prevent tooth loss. The Straumann Group currently employs approximately 3500 people worldwide. Its products and services are available in more than 70 countries through a broad network of distribution subsidiaries and partners.

Straumann Holding AG, Peter Merian-Weg 12, 4002 Basel, Switzerland.

Phone: +41 (0)61 965 11 11 / Fax: +41 (0)61 965 11 01

Homepage: www.straumann.com

Corporate Communication

Mark Hill: +41 (0)61 965 13 21

Thomas Konrad: +41 (0)61 965 15 46

E-mail: corporate.communication@straumann.com

Investor Relations

Fabian Hildbrand: +41 (0)61 965 13 27

E-mail: investor.relations@straumann.com

Disclaimer

This release contains certain forward-looking statements that reflect the current views of management. Such statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Straumann Group to differ materially from those expressed or implied in this release. Straumann is providing the information in this release as of this date and does not undertake any obligation to update any statements contained in it as a result of new information, future events or otherwise.

Straumann Media Releases subscription:

<http://www.straumann.com/en/home/media/media-releases.news.rss>

Straumann Social Media Channels

<http://www.straumann.com/en/home/about-straumann/social-media.html>

RSS feed subscription:

<http://www.straumann.com/en/home/media/media-releases.news.rss>

Straumann Media Center

smc.straumann.com

Login: "Corporate"; Password: "corporate"

¹ J. Derks, D. Schaller, J. Håkansson, J.L. Wennström, C. Tomasi, and T. Berglundh: Effectiveness of Implant Therapy Analyzed in a Swedish Population: Prevalence of Peri-implantitis: Journal of Dental Research 2016, Vol. 95(1) 43–49.

² Defined as bleeding on probing/ suppuration and bone loss > 2mm.

³ Buser D et al Clin Implant Dent Relat Res. 2012 Dec;14(6):839-51.

⁴ Rocuzzo M et al Clin Oral Implants Res. 2014 Oct;25(10):1105-12.

⁵ van Velzen FJ et al Clin Oral Implants Res. 2014 Nov 5.

⁶ Fischer K et al Clin Implant Dent Relat Res. 2012 Dec;14(6):808-15.

⁷ Derks J. et al. Published online before print December 11, 2014, doi: 10.1177/0022034514563077 JDR December 11, 2014.